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Multicentric Castleman's Disease (MCD) is a rare non-
malignant lymphoproliferative disorder presenting systemic
symptoms such as fever, night sweats, fatigue, anemia, effusions
and multifocal lymphadenopathy.1 Human herpes virus type 8
(HHV-8) is known to cause MCD in HIV patients and IL-6 and
VEGF may contribute to non-clonal lymphoproliferation and
unique manifestations, but the etiology of non-HIV MCD is not
clear.1 Here, we describe the ﬁrst case of MCD with increased
CD3þTCRabþCD4CD8- double-negative T (DNT) cells and
impaired lymphocytic apoptosis.
A 37-yearoldwomanwith a history of type-I diabetes andGrave's
diseasewas admitted to our hospital for evaluation of diffuse ground
grass opacities, small nodules inboth lungﬁeldswith hilar andmedi-
astinal lymphadenopathy in chest radiographs and computed to-
mography (Fig. 1a, b). On admission, she had fatigue, dyspnea and
slight fever with normocytic anemia, polyclonal hypergammaglobu-
linemia, and elevations of C-reactive protein and soluble IL-2 recep-
tor (1410U/ml). Noneof bacteria, fungi, or viruses includingHIV, EBV,
and HHV-8 was detected in her peripheral blood. In contrast, anti-
nuclear antibody anti-SSA, and rheumatoid factor were positive, in
addition to endocrine disorder-related autoantibodies, but she did
not show any ﬁndings that suggest rheumatoid disorders.
To make a deﬁnite diagnosis, a surgical lung and mediastinal
lymph node biopsy was performed. Histopathological ﬁndings
showed inﬁltration of polyclonal and IgG4-negative plasma cells
(Fig.1c, d), and plasma IL-6 (23.1 pg/ml) and VEGF (667 pg/ml) levels
were elevated. Theseﬁndings supported the diagnosis ofMCD.How-
ever, she showed no neuropathy, skin abnormality, neuropathy or
edema, and clonal plasma cells were not detected in her bone
marrow, negating the POEMS syndrome.2 We next focused on her
unique family history. Of note, her mother and brothers also had
autoimmune endocrine disorders, suggesting that genetic basis
may underlie her autoimmune endocrine disorders and MCD. Auto-
immune lymphoproliferative syndrome (ALPS) is another rare non-
malignant lymphoproliferative disorder associated with increased
DNTcells (Fig. 2) andapoptosis defect of lymphocytes (Fig. 3), usually
due to inherited genetic abnormality in the apoptosis-related
pathway.3 Therefore, we enumerated DNT cells, which are hallmark
of ALPS that shows both familial autoimmune disorders and nonma-
lignant proliferation of lymphocytes. Interestingly, ﬂowcytometry ofPeer review under responsibility of Japanese Society of Allergology.
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DNT cells (4.9% in total T cells) beyond the criterion of ALPS
(>2.5%). Increased proportions of DNT cells were also observed in
hermother and brother as well as autoimmune endocrine disorders,
conﬁrming familial predisposition of a DNT cell expansion. In addi-
tion, she showed increased survival of phytohemagglutinin-
activated Tcells after incubation in the presence of anti-Fas antibody
andmethylprednisolone, but not 50 mMC2-ceramide, suggesting the
impairment of Fas-induced apoptosis. We also found elevated
plasma IL-18 level (866 pg/ml), which is another accessory criterion
of ALPS (>500 pg/ml). However, in spite of her several ALPS-like fea-
tures, her clinical featureswerenot sufﬁcient to bediagnosed asALPS
becausemutation in FAS genewas not detected in her lymphocytes.4
MCD is a polyclonal lymphoproliferative disorder with systemic
manifestations due to increased IL-6. In patients with HIV, HHV-8
infection may lead to MCD, however, the etiology of non-HIV
MCD has not been clariﬁed to date.1 In small numbers of patients,
plasma cell myeloma contributes to development of MCD, espe-
cially in the POEMS syndrome, but in majority of patients with
MCD, the pathogenesis including the origin of IL-6 production is
not known. Our present case hadMCDwith ALPS-like features, sug-
gesting the possibility that lymphoproliferation driven by impaired
lymphocytic apoptosis led to the clinical features of MCD, although
increased proportion of DNT cells and mutations in the apoptosis-
related genes have not been reported in MCD.
It has been reported that Fas/Fas ligand-deﬁcient lpr and gldmice
show an increase of DNTcells, autoimmunity, and lymphoprolifera-
tion with massive and systemic enlargement of lymph nodes.5 His-
tological evaluation of lymph nodes of thesemice shows blurring of
nodal architecturewith lymphocytic proliferation of histiocytes and
plasma cell.5 In addition, the histological feature of enlarged lymph
node in ALPS is reactive follicular hyperplasia, often with focal pro-
gressive transformation of germinal center and polyclonal plasma-
cytosis.6 The histological ﬁndings of our case, which showed the
features of MCD including polyclonal interfollicular expansions of
plasma cells, may resemble with those seen in Fas/Fas-ligand deﬁ-
cient lpr and gldmice, suggesting the involvement of impaired lym-
phocytic apoptosis in the pathogenesis of MCD in our case.
Our patient was not diagnosed as having ALPS in spite of her
several ALPS-like clinical features. The lack of mutations in the FAS
gene was one of the main reasons why her clinical characteristics
did not fulﬁll the criteria of ALPS, however, it has been reported a ge-
netic abnormality other than FAS mutation in majority of patients
with ALPS.7 In fact, mutations in FAS ligand, caspase-8,-10 and neu-
roblastoma RAS8,9 were found in patients with ALPS. In the present
case, although all possible gene mutations have not been analyzed,evier B.V. All rights reserved.
Fig. 1. HRCT of the chest at diagnosis shows bilateral centrilobular nodules, thickening of the interlobular septa and mediastinal lymphadenopathy (a, b). Histological ﬁndings of the
lung (c) and mediastitial lymph node (d) show inﬁltration of polyclonal and IgG4-negative plasma cells around the bronchovascular bundles and in the interfollicular areas of the
nodes (H&E A 40, B 200).
Fig. 2. Double-negative T (DNT) cells in the peripheral blood mononuclear cells (MNCs). Four-color ﬂow cytometry showed increased proportion (4.9%) of CD4CD8- DNT cells in
the abTCRþCD3þ fraction (Gate X3). In control MNCs from 3 healthy individuals, proportions of DNT cells were less than 0.1% (data not shown).
Fig. 3. Relative cell survival after apoptosis assay. Peripheral blood mononuclear cells
taken from the patient with ALPS and 2 control healthy individuals were incubated in
the RPMI supplemented with 10% fetal bovine serum and 2 U/mL IL-2. During incuba-
tion, cells were stimulated by phytohemagglutinin (PHA) for 6 h at days 0 (1 mg/mL)
and 12 (0.1 mg/mL) and washed. At day 18, cells were collected and anti-Fas antibody
(1 mg/mL), methyl-predonisolone (mPSL; 100 mM), C2 ceramide (50 mM), or control me-
dium was added. After further incubation in the presence of these reagents for 18 h,
proportions of survived cells were evaluated using trypan blue, and percentages of
cell survival in the presence of indicated reagents relative to cell survival after incuba-
tion with control medium were calculated.
Letter to the Editor / Allergology International 64 (2015) 112e114 113increased count of DNTcells observed not only in our case but also in
her family members suggests a genetic abnormality other than FAS
mutation may underlay the pathogenesis of the patient.
The clinical features of our case suggest the possible relationship
between MCD and ALPS. However, there are some differences be-
tweenMCD and ALPS. The majority of ALPS patients have mutations
in apoptosis-related genes such as FAS, whereas it is not clear
whether MCD patients have these mutations. In addition, a raised
DNT cell subset has not been reported in MCD. Furthermore, serum
IL-6 level is normal or mildly elevated in ALPS.10 However, MCD has
many variants, as several different histological patterns show, and
ALPS, the syndrome may also have many variants, as several known
or unknown genemutations show. In this regard,MCD-ALPS overlap
may exist, and the present case would be included in the category.
This patient has been treated with oral corticosteroid, because
corticosteroid is used as the treatment for both ALPS and MCD.
However, efﬁcacy of predonisolone has been insufﬁcient for lymph-
adenopathy and pulmonary inﬁltration in our patient, and optimal
treatment for impaired lymphocyte apoptosis, including ALPS, re-
mains to be controversial. Immunosuppressive drugs and immuno-
therapy for B lymphocytes with anti-CD20 rituximab has been
attempted for ALPS, but their clinical efﬁcacy and safety should
be further investigated.3,11
Letter to the Editor / Allergology International 64 (2015) 112e114114In conclusion, the ﬁrst case of MCDwith increased DNTcells and
impaired lymphocytic apoptosis described here provides the
further evidence for understanding the pathogenesis of MCD.
Although the present case suggests possible involvement of
impaired lymphocytic apoptosis in the pathogenesis of MCD, we
need more cases to clarify the relationship between MCD and
ALPS as well as optimal therapy for these patients in the future.Conﬂict of interest
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